Sanofi-aventis Partner to your idea

Partner to
your idea
10/11
2/3
12/13
4/5
14/15
16/17
6/7
18
8/9
19
10/11
20/21
Contents
page
12/13
14/15
16/17
18
19
20/21
2/3
AT A GLANCE
4/5
CREATING VALUE THROUGH PARTNERSHIPS
6/7
VACCINES
8/9
RESEARCH & DEVELOPMENT
10/11
ONCOLOGY
DIABETES
12/13
Ophthalmology
Aging
14/15
Fibrosis and wound repair
Infectious Diseases
16/17
Immuno-inflammation
Biologics
18/19
Exploratory Unit
Asia Pacific
Early to Candidate
Lead Generation to Candidate Realization
20/21
Pharmaceutical Customer Solutions
Prospective and Strategic Initiatives
22/23
Worldwide connected network of selected partners
Recent deal flow overview
24
Industrial Affairs
Sales & Marketing
2/3
4/5
6/7
8/9
10/11
12/13
14/15
16/17
18
19
20/21
CHRISTOPHER A. VIEHBACHER
Chief Executive Officer
Sanofi-aventis
What empassions me most about our industry is that it never slows down or stops evolving.
After centuries of research, the explosion of science is palpable all around us and the
opportunity for innovation is simply astounding. Sanofi-aventis has always been regarded
as one of the world’s leading R&D based companies and more recently, we have also been
recognized as a partner of choice. With 33 external deals signed in 2009 alone, 20 of which
were in R&D, the success of our partnership strategy is clear, but why? The reasons are
manifold but, put simply, it is because we understand.
We understand the need to foster an environment where scientists and developers have
the freedom to think and create. As result of our history and experience, we understand the
science and the real public health needs of tomorrow. We understand the markets and have
the resources and expertise to ensure products can move through the pipeline to the market
as fast as possible, whilst ensuring adherence to the highest safety and quality standards.
And through our diverse culture and geographical spread, the network of sanofi-aventis can
ensure access to both traditional and emerging markets, local knowledge and the production
and commercialization of the approved products. But, most importantly, we understand
that our partners have their own objectives, a culture specific to their team and a need for a
partner to work collaboratively to create success for both.
The research paradigm is changing and whilst we will continue to foster innovation within
the company, we realize that in order to respond to patients’ needs in the future, we need
to work together and create partnerships wherever the best science and technology may
be. By pooling the creativity and expertise of world-renowned researchers and professionals
internally and externally, together with our partners we can ensure the best innovations,
which will ultimately lead to discoveries benefiting the existing and future patients that are
waiting for us.
1
At a glance
Sanofi-aventis’ ambition is to become a diversified
global healthcare leader, focused on patients’ needs.
Group strategy is based on three key principles in
order to deliver long-term sustainable growth:
• Increasing innovation in Research & Development
• Seizing external growth opportunities
• Adapting group structures for future challenges
Sanofi-aventis has core strengths in the field of
healthcare with five growth platforms: emerging markets,
vaccines, consumer healthcare, diabetes treatment,
innovative products and cancer treatment.
29,306
€29,306 m
2009 net sales – Gross of 6.3%
compared with 2008
on a reported basis
22 105,000
4,5834th 110
Approximately
105,000
22
employees WORLDWIDE
RESEARCH &
DEVELOPMENT SITES
€4,583 m
PRESENT IN
4th
investment in r&d in 2009
Representing 15.6% of net sales
largest pharmaceutical group
in the world as of end 2009
110
countries
A WORLD
LEADER
N°2
N°1
N°3
N°5
IN HUMAN
VACCINES
IN EUROPE
IN EMERGING
MARKETS
IN ANIMAL HEALTH
AS OF END 2009
IN CONSUMER HEALTHCARE WITH THE
ACQUISITION OF CHATTEM, OUR NEW
US CONSUMER HEALTCARE PLATFORM
5 Growth platforms*
€7,356 m +19.0%
EMERGING MARKETS
€3,774 m +19.4%
DIABETES BRANDS
€3,483 m +19.2%
VACCINES
CONSUMER HEALTHCARE
€1,430 m +26.8%
NEW PRODUCTS
* 2009 net sales, growth is at constant exchange rates.
2/3
Creating value
through partnerships
Openness to
discovery
“This is a collaborative relationship without
restrictive preconditions between two leading
organizations.
Our scientists will continue to freely explore
cutting-edge research and publish their work,
with the added benefit of advancing the science
through this unique association that provides
access to extensive resources at sanofi-aventis.
Further collaboration and scientific exchange will
be reinforced through annual Salk/sanofi-aventis
research retreats and extended working lab visits
between scientists from both organizations.”
William BRODY,
CEO SALK
The Salk Institute for Biological Studies in La Jolla, California, is
an independent non-profit organization dedicated to fundamental
discoveries in the life sciences, the improvement of human health
and the training of future generations of researchers.
The sanofi-aventis Regenerative Medicine Program at the Salk
Institute is a close research collaboration to support the Institute’s
stem cell facility and provide flexible financial support to individual
scientists to accelerate innovative research projects in public health.
18
33 2
33
Partnerships and
acquisitions in 2009
18
2
R&D partnerships/
in-licensing deals
SIGNed IN 2009
R&D ACQUISITIONS
IN 2009
“
Professional teams
dedicated to
your ideas
“Prior to founding Alopexx I was involved
with in-licensing activities at several
large pharmaceutical companies. I know
firsthand the efforts it takes for a team
to properly evaluate and license an
opportunity. The professionalism,
diligence and responsiveness displayed
by sanofi’s in-licensing team were of
the highest caliber. We are investigating
novel approaches to the treatment and
prevention of staphylococcal and other
bacterial infections.
We were gratified to see the sanofi team’s
grasp of the potential and clinical utility of
our antibody.
We continue to be impressed with
the input and guidance provided by
sanofi as we move forward with clinical
development.
It gives us the greatest confidence
that ongoing and future plans with
our antibody will meet with similar
interactions and success.”
Daniel VLOCK, CEO Alopexx
Novel
collaboration
structures
“We are delighted to have established this global partnership
with sanofi-aventis, a world leader in healthcare.
This partnership, effective today with a leading actor at the
forefront of life sciences, should enable us to better showcase
French research abroad. We are very pleased to stand side-byside with sanofi-aventis to conduct research from fundamental
science to patient application.”
Pr. André SYROTA, Chairman of AVIESAN
Sanofi-aventis signed in February 2010 a
research partnership with AVIESAN (the
French Life Sciences and Healthcare
Alliance), comprised of the CEA, CNRS,
INRA, INRIA, Inserm, Institut Pasteur, IRD,
Conference of University Presidents and
Conference of regional and university
hospital CEOs. This is the first time such
a partnership has been signed with all
the players of the academic research
community in the field of healthcare in
France.
“We are very pleased to have entered into
this partnership with the National Alliance
for Life Sciences and Healthcare, which is a
major breakthrough in terms of public-private
partnerships in France.
By pooling the creativity and expertise of a
multitude of world-renowned researchers, we
are sure that this fruitful collaboration will
boost innovation in life sciences in France,
and ultimately lead to major discoveries that
will benefit patients.
Through this agreement, sanofi-aventis
confirms once again its commitment to
developing research and innovation in
France.”
Christopher A. VIEHBACHER
CEO of sanofi-aventis
4/5
Vaccines
Sanofi pasteur, the vaccines division of sanofi-aventis
group is seeking partners who will share the company’s
pursuit of innovation and drive for excellence. Our
diverse culture and geography allow us to collaborate
effectively with a broad array of partners around the
world. We are not only at the forefront of conquering newly
targeted diseases, but also leading the way in expanding
immunization across all age groups, including adolescents
and the elderly. This leadership has translated into
outstanding success in the industry, and our company
has experienced a recent period of unprecedented growth.
12,500
491 3,483
€491 m
in r&d investments
in 2009
12,500
employees
€3,483 m
2009 NET SALES IN VACCINES
Sanofi pasteur is interested in potential partnering opportunities
in the field of active and passive human immunization.
Domains of interest
Vaccines, monoclonal antibodies and supporting technologies for
prevention and treatment of infectious diseases:
• Novel antigens for vaccine development
• Monoclonal antibodies, including antigens as targets for monoclonal
antibody development
• Antigen discovery and characterization
• Carrier proteins and protein-polysaccharide conjugation methods or
alternative technologies
Existing alliances/
partnership:
•
•
•
•
•
BD (Becton, Dickinson and Company)
Chumakov Institute
CSL
KaloBios
Syntiron
Agents to enhance vaccine immune responses – such as adjuvants and
immunomodulators:
• Adjuvants, particularly those that drive Th1 and Th2 immune responses
• Vaccine vectors intended to enhance or modify immune responses
• Characterization, modulation and assay of protective immune responses
• Areas of basic immunology applicable to vaccine development, such
as studies of innate immunity, immune escape mechanisms, and
immunoregulation
New vaccine delivery systems:
• New ways to administer vaccines
• Vaccine vectors suitable for nasal or oral use
Partnering Contacts
Tools for improving vaccine and monoclonal antibody research,
development and production:
• Animal models of human diseases
• Development and application of new technologies in the areas of
genomics and proteomics
• Bioinformatics techniques for data handling and analysis
• Prokaryotic or eukaryotic cell lines for antigen production
• Fermentor and bioreactor technology
• Downstream processing and purification processes
• Preservatives and stabilizers
• Identification of biological markers for evaluating the efficacy of
prophylactic or therapeutic interventions for infectious diseases
• Epidemiological studies relevant to the use of vaccines and
immunotherapeutics
Jeffrey Almond, PhD
Vice President, Discovery and External
Research & Development
Campus Mérieux
1541 avenue Marcel Mérieux
69280 Marcy L’Étoile – France
Tel: +33 4 3737 9453
[email protected]
Allan Jarvis, Jr. PhD
Vice President, Corporate Development
Sanofi pasteur Inc.
Discovery Drive
Swiftwater PA 18370, USA
Tel: +1 570 957 5525
[email protected]
For more information please visit www.sanofipasteur.com
6/7
Research &
Development
From preferred partners to preferred networks:
A commitment to health.
The objective of sanofi-aventis R&D is to find new solutions to address
the individual patient’s needs by understanding disease processes and
actively integrating that understanding into healthcare management.
At this time of unprecedented opportunities, and considering the
complexity of today’s science, creative solutions and continued
research collaboration are required. The new sanofi-aventis R&D
values networks and focuses on partnership and collaboration.
Aiming to incorporate innovation into the main fabric of R&D, we set
up a unique structure revolving around networks of creativity spread
across regions, technologies and scientific areas of excellence.
Supporting these networks are disciplined and efficient core
processes, creating a performance-driven environment that fosters
fast decision-making and the empowerment of our teams.
Our strategic vision for R&D focuses on seven major areas with critical
unmet medical needs: Diabetes, Oncology, Ophthalmology, Aging,
Infectious Diseases, Fibrosis & Wound Repair and Immuno-Inflammation,
while taking into account regional specificities with the establishment of
an Asia-Pacific R&D Center.
“Looking into the future, the
renewed R&D is moving a step
further from preferred partners
to preferred networks. Such
networks will not just serve
sanofi-aventis and individual
institutions or laboratories,
rather it will enable all partners
within the network to access
the resources and expertise of
everyone else so as to form a
vibrant research ecosystem and
create more value than we ever
could alone – for improving health
throughout the world.”
Marc Cluzel
Executive Vice President
Research & Development
22
11,0
15.6
60
31
22
RESEARCH &
DEVELOPMENT SITES
11,000
APPROXIMATE NUMBER OF
R&D EMPLOYEES WORLDWIDE
EXCLUDING VACCINES
€4,583 m
2009 RESEARCH AND
DEVELOPMENT SPEND
REPRESENTING
15.6%
OF NET SALES
60%
of the compounds in our
pharma portfolio is developed
through partnerships
as of APRIL 2010
31%
of our pharma portfolio
is composed of biological
compounds as of APRIL 2010
8/9
Oncology
Sanofi-aventis’ Oncology Division – a new and unique organization merging
patient needs and innovative science – was recently created as part of
current transforming efforts and demonstrates sanofi-aventis’ commitment to
oncology as a major strategic pillar. The Oncology Division is a fully integrated
business unit comprising the full R&D chain from discovery to development
and commercialization. Its goal is to provide solutions that have a major impact
on patients with cancer – a Patient Focused Innovation Strategy – and, in the
process, to build a sustainable oncology business.
The division is headquartered in Cambridge, MA, USA, one of the world’s most important
centers for biotech research and Vitry-sur-Seine, France, where a significant part of
sanofi-aventis’ oncology research and development activities have been historically
located. These dual locations in the US and Europe will provide us with excellent
opportunities to forge strategic external partnerships, leverage the local talent, and
embrace many of the successful elements from the biotech employee culture –
including accountability, creativity, and entrepreneurialism. It is supported by
sanofi-aventis’ corporate R&D network with clinical research units in several countries
and a biotechnology platform for monoclonal antibodies in Vitry-sur-Seine, France.
Existing alliances/
partnership:
•
•
•
•
•
•
Dyax
Exelixis
ImmunoGen
Merrimack
Micromet
Regeneron
Domains of interest
Scientific areas:
• Growth and development pathways related to cancer
dependence
• Synthetic lethality
• Cancer metabolism related to cancer dependence
• Targeted therapies and technologies enabling targeted
therapies
• Companion diagnostics
• Innovative therapies that provide substantial
improvements for patients
• Best in class and/or first in class;
small molecules or biologics
• Compounds suitable for combination therapy aimed at
additive/synergistic effects, in particular with
sanofi-aventis commercialized or pipeline products
• Supportive care products if demonstrated benefit over
existing therapies
Development Stage:
• Discovery or pre-clinical stage through all clinical
development stages to already commercialized
oncology products
Partnering Contacts
External Opportunity contact:
Alain Curaudeau
VP and Head of Strategy & Portfolio Management
Global Oncology Division
Sanofi-aventis, US, Inc
200 Crossing Blvd, BX2-812A
Bridgewater, New Jersey 08807, USA
Tel: +1 908 231 4000
[email protected]
Business Development contact
Tanja S. Weber
VP Oncology
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
Diabetes
Sanofi-aventis’ Diabetes Division is a newly created and fully integrated
structure comprising all functions working on diabetes from discovery to
commercialization in our 12 major markets. The Diabetes Division portfolio
generated €3.8 bn sales in 2009 including a broad spectrum of therapeutic
solutions, the Division offers a full range of devices to simplify usage of
insulin for patients, soon to be complemented by easy-to-use and reliable
blood glucose monitors.
The division ambition is to become a “360°” partner of the patient: delivering bestin-class and integrated solutions to diabetic patients. The division is committed
to place the patient in the heart of the organization through the integration of new
pharmacological targets and innovative approaches and the seamless connection of
diagnostics, treatment and monitoring.
To leverage the inspiring heritage from Hoechst that has made sanofi-aventis
a strong partner for diabetic patients and healthcare professionals for over 85
years, Frankfurt will serve as the primary site for product and device innovation.
Acknowledging diabetes as a truly global epidemic, 2 secondary locations are
established in France and the US ensuring the appropriate connectivity with global
stakeholders and patients worldwide.
Domains of interest
Scientific areas:
New approaches to improve the daily life of patients with diabetes, in particular:
• Innovative approaches for the diagnosis, prevention and treatment of Type 1
and/or Type 2 diabetes
• First in class and best in class therapeutics
(small molecules, insulins and other biologics) and vaccines
• Microvascular and defined macrovascular (central and peripheral)
complications of diabetes, wound healing
• Regenerative medicine incl. stem cells for use in diabetes
• Innovative device approaches, monitoring systems and integrated solutions
• Biomarkers, diagnostics, and bioinformatics
• Systems biology (biologic insights into mechanisms for target selection)
• Personalized therapies in diabetes
• Formulation technologies aimed at improving existing or future products
• Compounds and approaches for combination therapy in particular
with sanofi-aventis products
• Prevention of diabetes (Hypercholesterolemia, Obesity etc.)
• Anti-inflammatory therapies with impact on diabetes
Development Stage:
• Discovery or pre-clinical stage through all clinical development stages to
already commercialized diabetes products
Existing alliances/
partnership:
•
•
•
•
AgaMatrix
CureDM
Wellstat Therapeutics
Zealand Pharma
"We are excited to partner with
sanofi-aventis because they share our
core beliefs – people with diabetes need
more accurate blood glucose meters and
our technology delivers high accuracy.
With their global presence and sterling
reputation, we believe this partnership will
enable patients worldwide to easily access
high accuracy blood glucose testing."
Sonny Vu and Sridhar Iyengar
Co-Founders of AgaMatrix
Partnering Contacts
External Opportunity contact
Ulrich Stilz
Global Head of Innovation & External
Networking – Diabetes Division
Industriepark Hoechst, Bldg G838
D- 65926 Frankfurt am Main
Tel: +49 69 305 80710
[email protected]
Business Development contact
Christian Lerche
Associate VP Diabetes & Metabolism
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
10/11
Ophthalmology
Ophthalmology is a high potential market, which is expected to grow
significantly over the years to come. This growth is likely to be driven
by innovation and new products, premium pricing with no significant
reimbursement issues and societal trends, such as aging populations
and the diabetes epidemics.
Created in 2005, Fovea Pharmaceuticals is a biopharmaceutical company,
specialized in development and commercialization of drugs for the treatment of
ocular diseases and based at the Institut de la Vision in Paris (France). Fovea has
a portfolio of three clinical compounds, a unique technology platform and several
discovery programs dedicated to back of the eye diseases.
Acquisition of Fovea Pharmaceuticals and the gene therapy collaboration with
Oxford Biomedica, both accomplished in 2009 were the first steps towards the
recent creation of the Ophthalmology Division of sanofi-aventis. This new division
will combine the expertise and resources needed from both Fovea and sanofi‑aventis
to significantly grow the business and demonstrate the efficacy of products through
regulatory clinical development. With this goal in mind, the Ophthalmology Division
is interested in further examining potential partnering opportunities in the field of
ocular diseases.
Existing alliances/
partnership:
•
•
•
•
•
•
•
•
•
•
Dyax
Genzyme
John Hopkins University
Montreal University
ORA
Oxford Biomedica
Paris Vision Institute
Pennsylvania University
Regeneron
University of Geneva
Domains of interest
Agents and devices to treat retinal diseases:
• Dry atrophic Age-related Macular Degeneration (AMD)
• Retinal vascular diseases: wet AMD, Retinal Vein
Occlusion (RVO), Diabetic Macular Edema (DME)
• Vitroretina surgery compounds and devices
Agents to treat ocular surface diseases:
• Persistent allergic conjunctivitis
• Dry Eye
• Uveitis
• Infection and inflammation
Agents to treat Glaucoma:
• Intra-ocular-pressure (IOP) lowering
• Neuroprotection
Drug Delivery Systems and Devices:
• Sustained delivery to the retina
• Glaucoma non topical sustained delivery
Imaging tools and Biomarkers:
• New Optical Coherance Tomography (OCT) and coupling
with Adaptative Optics
Partnering Contacts
FOVEA Pharmaceuticals
Institut de la Vision
17 rue Moreau, 75012 Paris – France
Tel: +33 1 44 16 42 43
www.fovea-pharma.com
Pierre Belichard
Chief Operating Officer
[email protected]
Marie-Laure Bouttier
Business Development Associate
[email protected]
Aging
There is an unprecedented, pervasive and enduring global demographic
change. The world’s population is aging and it has profound implications
for many facets of human life. The Aging Unit focuses on providing
integrated healthcare solutions for the elderly.
We aim to treat age-related diseases, globally, to provide practical
solutions for the elderly as well as to sustain their functional well-being.
Domains of interest
Quality of life:
• Chronic Pain
• Vitality and fatigue
• Circadian rhythm perturbations
• Hormonal changes
• Urogenital disorders, benign prostate hyperplasia, incontinence
Existing alliances/
partnership:
•
•
•
•
•
•
•
•
California Institute of Technology
DiaTral (Medicen)
IMI-EuroPain
MIT
Regeneron
Rockefeller University
Salk Institute
TRANSAL (Medicen)
Sensory disorders:
• Hearing disorders
• Aged-related ophthalmologic conditions
• Exploration of other sensory disorders (olfactory, taste)
Disabilities from cardiac, vascular and cerebral origin:
• Stroke: prevention and acute treatment-management of patients
after the event
• Alzheimer’s disease and related co-morbidities
• Parkinson’s disease
Musculoskeletal diseases:
• Osteoarthritis
• Osteoporosis
• Sarcopenia
Other domains of interest:
• Nutraceuticals and Cosmeceuticals
• Skin: healing, aging and bedsores
• Biology of aging – biomarkers of aging
– cell dysfunction (mitochondrial DNA), transcription factors and genes,
telomeres and longevity, cell homeostasis, metabolism and diet
• Stem cell therapy
• Delivery systems, new formulations, polypills, drug devices and technologies
designed to improve compliance, sensing technologies, adherence and
observance of drug treatment, and overall quality of life in the elderly,
personalized medicine
• E-health
Partnering Contacts
External Opportunity contact:
Kenneth I. Maynard
Head, Business Development Office
Sanofi-aventis, US, Inc.
200 Crossing Blvd, BX2-812A,
Bridgewater, New Jersey 08807 USA
Tel: +1 908 231 4000
[email protected]
Business Development contact:
Marion ROY
Associate VP Aging,
Cardiology & Internal Medicine
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
12/13
Fibrosis and Wound Repair
The injury and repair of tissues and organs has far reaching consequences for patients and thus represents an area of
growth potential for pharmaceuticals. From renal failure and cirrhosis to the rejection of transplanted organs, fibrotic
diseases are often devastating and usually debilitating, with few non-surgical options for patients. The research and
development of innovative healthcare solutions for the treatment of fibrosis, scarring or wound repair is an exciting
new area for sanofi-aventis. Any novel therapeutic must address unmet medical needs of patients and have potential
for superior benefits compared to current therapies, leading to a high probability for approval and reimbursement.
Healthcare solutions could include small molecules, bio-conjugated small molecules, peptides, proteins, microRNA,
RNAi, monoclonal antibodies, cell therapies and botanical therapeutics, which may potentially be combined with
innovative therapeutic delivery systems. The Unit’s scope extends from drug concept through clinical proof of concept.
Domains of interest
• Therapeutic solutions for tissue injury, fibrosis and wound repair including
small molecules, biologics, botanical drugs, tissue engineering...
• Technologies that improve diagnostics related to tissue fibrosis, re-modelling
or wound healing: Biomarkers and non-invasive technologies such as imaging
for patient stratification and clinical markers
• Enhanced drug delivery (parenteral delivery devices/technologies,
novel formulations, target organ delivery, sustained or controlled release
technologies)
• New mechanistic pathways or targets regulating responses to tissue injury
and repair processes
• Novel approaches to diseases whose pathology is associated with acute or
chronic tissue injury, such as idiopathic pulmonary fibrosis, acute/chronic
kidney diseases, liver fibrosis/cirrhosis, adhesions, excessive scarring
• Healthcare solutions for tissue repair, especially advanced wound care
Partnering Contacts
External Opportunity contact:
Chang S. Hahn Ph.D.
Director, Portfolio Strategies and
External Opportunities
Fibrosis and Wound Repair TSU
BRW G-303A, Route 202-206
Bridgewater NJ 08807 USA
Tel: +1 908 231 4000
[email protected]
Business Development contact:
John Orsato
Associate Vice-President,
Novel Therapeutic Approaches & Infectious Diseases
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
Existing alliances/
partnership:
• Regeneron
• Various academic collaborations
Infectious Diseases
The strategy of the group in Infectious Diseases aims to discover and
develop innovative healthcare solutions or compounds with superior benefits
for prevention, diagnosis and treatment of infectious diseases with high
medical need. Our key focus of internal and external innovation is on global
solutions for multi drug-resistant infections in hospitals and nursing homes,
together with sanofi pasteur, the Vaccines Division of the group, and solutions
for neglected diseases in developing countries, in alignment with our
Access to Medicines strategy.
Domains of interest
Multi-drug infections in hospital and nursing home settings
(Hospital – or community acquired – resistant infections)
• Anti-bacterials, anti-fungals and bacterial toxins inhibitors
• Prophylactic approaches (e.g. virulence factors, biofilms) and
other therapeutic needs
• Diagnostics, disinfectants
Neglected diseases in developing countries:
• Tuberculosis: treatment for non-resistant and resistant
tuberculosis. Treatment of latent tuberculosis infections
• Parasitic diseases: Malaria (uncomplicated/severe),
Leishmaniasis (visceral and cutaneous)/Sleeping sickness
(Human African trypanosomiasis, stage I/II), Chagas disease
• Other therapeutic needs
Host oriented compounds/healthcare solutions:
• Activity on human targets/pathways involved in
host response to pathogens (viruses, bacteria, parasites)
including prevention, treatment and other secondary effects of
infections
Preventive and therapeutic approaches are based on:
• Innovative targets, modes of action, technologies for identifying
new treatments
• Small Molecules or Natural Products
• Biologics (antibodies, proteins...)
• Others
Existing alliances/
partnership:
•
•
•
•
•
•
•
•
•
•
Alopexx
AVIESAN
DNDI
INNOMAD
John Hopkins University
MMV
Novozymes
Palumed
Regeneron
University of Chicago
Partnering Contacts
External Opportunity contact:
PETER HAMMANN, PROF. DR.
Head External Opportunities
Industriepark Hoechst, Bldg H 831
D-65296 Frankfurt Germany
Tel: +49 69 395 80710
[email protected]
Business Development contact:
John Orsato
Associate Vice-President,
Novel Therapeutic Approaches
& Infectious Diseases
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
14/15
Immuno-Inflammation
The mission of the Immuno-Inflammation Unit of sanofi-aventis R&D is to provide innovative healthcare
solutions in the interest and to the benefit of patients. Our current focus is on major immunological and chronic
inflammatory disorders of both genetic and epigenetic origin that represent true unmet medical needs today
and in the future. Multiple factors or processes such as the living environment, nutrition behavior or aging
status are known to markedly influence both severity and chronicity of clinical manifestations.
Domains of interest
• First in class and/or best in class, disease-modifying therapeutics
(small molecules, biologics, natural products, botanicals, RNA,
DNA , protein epitope mimetics, next generation antisense) aimed
toward common immuno-inflammatory diseases such as chronic
obstructive pulmonary disease (COPD), psoriasis, inflammatory
bowel disease (IBD), multiple sclerosis (MS), rheumatoid athritis
(RA) and asthma
• Leapfrogging, “game-changing” therapeutics addressing
underserved immuno-inflammatory diseases such as systemic
lupus erythematosus (SLE or Lupus), age-related macular
degeneration (AMD), IgA nephropathy, dermatomyositis, uveitis
• Technologies enabling targeted drug delivery to organ(s) of
interest that will lead to safer and more effective therapies for
patients with immuno-inflammatory diseases
• Formulation enhancements facilitating patient-focused solutions
to unmet patient and provider needs, such as more convenient or
otherwise improved dosing regimens (nanoparticles, microbiomebased delivery, improved devices, novel chemistry approaches to
drug metabolism)
• Proteome and genome-based patient care solutions including
phenotypic profiling, immunologic or genetic signatures,
sophisticated diagnostics or innovative bioassays
• Novel scientific insights into key signaling pathways common
to immuno-inflammatory conditions that will lead to improved
approaches to selective immunosuppression, mucosal repair,
disease susceptibility or modulation of immune system cross-talk
• Opportunities at any stage of development from discovery to proof
of efficacy
Existing alliances/
partnership:
•
•
•
•
•
•
•
•
Abbott
Hopital Civil de Lyon
John Hopkins University
Kyowa Hakko Kirin Co., Ltd
Mount Sinai Medical Center
NIH
Regeneron
University of California
Partnering Contacts
External Opportunity contact:
Patrick Griffin
Head, External Innovation and Opportunities
Immuno-Inflammation Therapeutic Strategy Unit
200 Crossing Boulevard
Bridgewater, New Jersey 08807-0890
Tel: +1 908 231 4000
[email protected]
Business Development contact:
Aude Le-Roux PhD
Associate VP
Immuno-inflammation
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 1 53 77 40 00
[email protected]
Biologics
Sanofi-aventis has the ambition to become a major player in the field of
Biotechnology. With this in mind, the group is proactively developing
external partnerships to increase the biologics portion in the sanofi-aventis
R&D portfolio through both internal and external innovation. This strategy
has already provided fruitful results to the group with its share of
biotechnology-sourced products in its pharma portfolio (excluding vaccines)
increasing from 14% in 2009 to 31% in April 2010.
Sanofi-aventis activities in biotechnology integrate the value chain from molecule
design to all development activities required for submission of biologic products.
The group has two fully integrated biotechnology platforms located in France
(Vitry-sur-Seine, near Paris) and Germany (Frankfurt-Hoechst site), plus a research
unit in the US. A major investment has been made in the Vitry-sur-Seine site to help
to create one of the largest cell culture biotechnology units ever built in France. In
addition, two specific innovation platforms of expertise are dedicated to nucleic
acid therapeutics and stem cells.
Domains of interest
Novel Therapeutics:
• Clinical-stage antibodies or other biological products with
the potential to address key unmet medical needs in the
sanofi‑aventis Therapeutic Strategy focus areas
• RNA therapeutics in late discovery or early clinical stages
• Stem cell and/or regenerative medicine products in early
clinical stages
Existing alliances/
partnership:
Products:
• Alopexx
• Dyax
• Kyowa Kirin
• Merrimack Pharmaceuticals
• Micromet
• Novozymes
• Regeneron
• Rockefeller University
Technologies & Manufacturing:
• BioWa
• Celltrion
• Dyax
• Lonza
• Regeneron
Basic Research:
• AVIESAN
• California Institute of Technology
• Harvard Stem Cell Institute
• Salk Institute
• Shanghai Institute for Biomedical Science
• University of Pennsylvania
New scaffolds:
• New protein scaffolds for next generation mono or multispecific biotherapeutics
New platforms and technologies:
• New cost effective manufacturing processes, including
miniaturized high-throughput platforms for media/culture
improvement
• Low cost efficient purification platforms for biotherapeutic
products.
• New assay methodologies
• New ways to rapidly select functional biological entities for
protein, nucleic acid or cell based applications
Manufacturing:
• Cost effective manufacturing facilities for rapid/flexible
generation of biological products
Partnering Contact
External Opportunity contact:
MELVYN HOLLIS
VP Bionetwork & Program Management
270 Albany Street,
Cambridge, MA 02139, USA
Tel: +1 617 679 5600
[email protected]
16/17
Exploratory Unit
Asia Pacific
Exploratory Unit (EU) is the primary source of early and open
innovation of sanofi-aventis. The mission of EU is to advance
basic scientific knowledge, to understand the underlying
causes of diseases and to translate emerging ideas into
validated concepts foreshadowing industrial applications for
patients’ benefits.
We address the specificities of the Asia-Pacific region by
developing adapted healthcare solutions for diseases
related to this region. These include specific cancers
(such as hepatocellular carcinoma, gastric, oesophageal
and nasopharyngeal); but also certain infectious diseases,
including Hepatitis B virus; among others.
EU activities are driven by scientific excellence and innovation and
bridge academic multi-disciplinary research with sanofi-aventis
scientists.
EU, in partnership with academic and advanced research
institutions, also assesses and incubates emerging ideas which
are too under-developed to get attention from other entities of
sanofi‑aventis R&D.
Extending its scientific networks, EU also fosters exchange
especially by integration of renowned visiting scientists within
EU teams.
We are also exploring emergent opportunities in Asia-Pacific
including traditional Chinese medicine, nutraceuticals, biosimilars,
stem cell research and personalized medicine.
Partnering Contact
Jean-Jacques Robert, Ph.D, MBA
Head of Partnering & Scientific Networks
Exploratory Unit, Centre de Labège
Voie La Pyrénéenne, BP37202
31672 Labège cedex – FRANCE
Tel: +33 5 61 00 43 04
[email protected]
“The partnership with sanofi-aventis
has greatly enhanced our ability of
translational research. Moreover, it
diversified the collaborative models for
domestic institutes like SIBS to work
with global pharmaceutical companies
like sanofi-aventis.”
Dr. Jiarui Wu
Vice President of SIBS
Partnering Contact
Geneviève Bellocq
Unit Management office Head
Sanofi-aventis R&D
1 avenue Pierre Brossolette
91385 Chilly Mazarin – France
Tel: +33 1 60 49 77 77
[email protected]
Early to Candidate
The mission of the Early to Candidate (E2C) Unit is
to take on validated concepts and early stage leads,
coming from sanofi-aventis or from academic or biotech
partners, and transform them into pharmacological
tools or (pre-)candidates with established therapeutic
orientations for clinical proof of concept, either within
sanofi-aventis or with external partners.
The Early to Candidate Unit is interested in validated concepts
and targets coming from all domains that will give rise to
innovative products within the six major areas of the group
(Diabetes, Oncology, Aging, Immuno-Inflammation, Infectious
Diseases, Fibrosis and Wound Repair) and any other
opportunistic areas of interest.
Partnering Contacts
Worldwide, France and rest of the world
Carole Fages, Ph.D, MBA
Head of E2C Unit Development Office
371, rue du Professeur Blayac
34184 Montpellier cedex 04 – France
Tel: + 33 4 99 77 78 79
e2c-fr&[email protected]
US
Paul R. Eynott, PhD
US Head, Partnering & Innovation
Early to Candidate Distinct Project Unit (DPU)
Sanofi-aventis, US
2090 East Innovation Park Drive
Oro Valley, Tucson, Arizona, 85755
Tel: +1 520 544 5801
[email protected]
Asia-Pacific
Alex Zhang, PhD
Asia-Pacific Head of E2C Unit
Sanofi-aventis R&D China
5/F, No.112 Jianguo Road, Chaoyang District
Beijing 100022, P.R.China
Tel: +86 10 6563 4936
[email protected]
Lead Generation to
Candidate Realization
The Lead Generation to Candidate Realization (LGCR)
platform identifies small molecule leads and progresses
them up to registration. The activities range from target
assessment and hit finding to dossier filing, including lead
generation and optimization, drug design, natural products
and CMC.
The Lead Generation to Candidate Realization platform in
return offers a unique integration of scientific expertise and
competencies from target to registration filings, in various fields
such as hit finding, structural biology, drug design, lead generation
and optimization and CMC development activities.
By sharing some of our key assets, capabilities and technology
platforms, LGCR will be your partner for adding value to your ideas
and compounds through a variety of collaborative and risk-shared
business models.
We are open and willing to turn R&D passion into fruitful
partnerships.
Domains of interest
•
•
•
•
•
•
•
Solutions for poorly drugable & intractable targets
Cellular disease models for phenotypic screening
Compound collections and focused libraries
Protein chemistry
Fragment based screening
Systems biology informatics
High potent chemistry and new synthetic chemistry
technologies
• Drug Delivery Systems and Process Technologies
Partnering Contact
Denis Croisat, Ph.D
LGCR Sourcing & External Business opportunities
Sanofi-aventis
1, avenue Pierre Brossolette
91385 Chilly Mazarin cedex – FRANCE
Tel: +33 1 60 49 77 77
[email protected]
18/19
Pharmaceutical Customer Solutions
Pharmaceutical Customer Solutions (PCS) is sanofi-aventis global center of
excellence in prescription medicine beyond oncology and diabetes to address
the needs of our various customers: patients and their families, healthcare
professionals and payors.
PCS combines the expertise from Medical and Marketing teams but also Market Access,
Customer Insight Assessment, Forecasting, Patrimony Management and Product
Communications, with the commitment to:
• define and orchestrate global product strategies, for major brands;
• transform promising compounds and projects under development into innovative
therapeutic solutions improving patient healthcare and quality of life.
PCS partners with R&D, Business Development and Industrial Affairs to accelerate the
identification of attractive opportunities for unaddressed patient needs in a systematic
and proactive way.
Our scope of activity covers the following:
Products : Prescription products, except Diabetes, Oncology,
Vaccines and Generics
Disease Areas: Priority given to diseases where sanofi-aventis
has an established portfolio and know-how, but also to any
attractive unmet medical need especially if consistent with our
R&D’s strategic priorities
Healthcare Services: Our ambition is not only to market
products per se but also to develop devices and services
fueling our brand equity
Existing alliances/
partnership:
We have a long history of partnerships
for the licensing, co-promotion or
co-marketing of products, such as our
alliances with:
• Bristol-Myers-Squibb
• Daiichi-Sankyo
• Procter & Gamble
These partnerships have ensured the
worldwide success of: Plavix®, Aprovel®,
Actonel® and Tavanic®
Domains of interest
• Co-development, licensing, co-marketing, co-promotion of
innovative prescription products
• Innovative device approaches
• Healthcare services bringing solutions to our customers
(patients, healthcare professionals, payors):
– improved continuum of care and disease management,
– better access to health information,
– patient quality of life and peace of mind,
– improved treatment adherence.
Partnering Contacts
Partnerships on anti-arrhythmic drugs and
cardiac rhythm management devices:
Aurélie-Anne CHAUSSE
Senior Manager, New Business Opportunities
Tel: +33 1 55 71 40 00
[email protected]
Partnerships on Plavix®, Aprovel®/Avapro®
or associated fixed-dose combinations:
Dominique ROOME
Associate Vice-President, Strategic Mature Products
Tel: +33 1 55 71 40 00
[email protected]
Partnerships on heparins:
Alexandre MOREAU
Vice-President, Global Strategy – Heparins
Tel: +33 1 55 71 40 00
[email protected]
Projects linked to prescription
drugs in all other therapeutic areas:
Ophra REBIERE
Vice-President, Strategic Portfolio Expansion
Tel: +33 1 55 71 40 00
[email protected]
For any other healthcare solutions
(including devices and services):
Emma GARDE
Senior Project Manager,
Healthcare Solutions & Partnerships
Tel: +33 1 55 71 40 00
[email protected]
Mail address:
174 avenue de France
BP374
75635 Paris cedex – FRANCE
Prospective and Strategic Initiatives
Dedicated teams close to you, all over the world
Prospective and Strategic Initiatives (PSI) is an R&D department committed to
anchoring sanofi-aventis in innovation hotspots and bringing distinctive external
opportunities to all units and platforms.
In addition to its global scouting organization, with dedicated teams in some of the top innovation
hotspots around the world, PSI contributes to the assessment of external opportunities, leads
major alliances and consortia, drives strategic initiatives in R&D and incubates some of the new
platforms.
Prospective and Strategic Initiatives’ scouting and partnering teams are fully dedicated to:
• Being globally connected
• Being locally active and embedded in local innovation ecosystems
• Identifying and working with local innovators and bringing their ideas, concepts and energy to
the best, most appropriate contacts within the sanofi-aventis group
Being as close and accessible to you is our aim, knowing you better and interacting efficiently
with you is our will and partnering with you is our determination.
Jacques DELORT
Vice President
Prospective Strategic Initiatives
Partnering Contacts
US
Germany
Shiv Krishnan, PhD
Senior Director, Scouting & Partnering
Sanofi-aventis R&D, 1041 Route 202-206
Bridgewater, New Jersey 08807, USA
Tel: +1 908 541 5333
s&[email protected]
US – West Coast
Harald Pacl, PhD
Senior Director Scouting & Partnering Germany
Sanofi-Aventis Deutschland GmbH
D-65926 Frankfurt am Main, Germany
Tel: +49 69 305 80644
s&[email protected]
France and rest of the World
Rémi Brouard, MD.
Vice President Scouting & Partnering
Sanofi-aventis office in San Diego:
Scripps Translational Science Institute building
3344 North Torrey Pines Court, suite 300
La Jolla, California, 92037 USA
Tel: +1 858 558 85 28
s&p-westus.psi @sanofi-aventis.com
Isabelle Thizon-de-Gaulle, MD
Vice President Scouting & Partnering
France & rest of the world
174 avenue de France
75635 Paris cedex 13 – France
Tel: +33 0 1 53 77 40 00
s&p-fr&[email protected]
US – North East
Sridaran Natesan, Ph.D.
Senior Director, Scouting & Partnering
Prospective & Strategic Initiatives
Sanofi-aventis
270, Albany Street, Cambridge, MA 02139
Tel: +1 617 679 5717
s&p-eastus.psi @sanofi-aventis.com
20/21
Worldwide Connected Network
of Selected Partners
EUROPE
Biotech
• Genfit, Lille, France
• Novozymes, Bagsvaerd, Denmark
• Oxford BioMedica, Oxford, UK
• Zealand Pharma, Glostup, Denmark
USA
Biotech
• AgaMatrix, Salem, NH, USA
• Alopexx, Cambridge, MA, USA
• CureDM, Wilmington, DE, USA
• Dyax, Cambridge, MA, USA
• Exelixis, San Francisco, CA, USA
• ImmunoGen, Cambridge, MA, USA
• Merrimack, Cambridge, MA, USA
• Micromet, Bethesda, MD, USA
• Regeneron, Tarrytown, NY, USA
• Syntiron, St Paul, MN, USA
• Wellstat, Gaithersburg, MA, USA
Academia
• California Institute of Technology, Pasadena, CA, USA
• Johns Hopkins University, Baltimore, MD, USA
• Rockefeller University, New-York, NY, USA
• Salk Institute for Biological Studies, La Jolla, CA, USA
• University of Pennsylvania, Philadelphia, PA, USA
Acquisition
• BiPar Sciences, CA, USA
Academia/CONSORTIA
• AVIESAN (French Life Sciences
and Healthcare Alliance)
• Innovative Medicines Initiative (IMI) –
European Public Private Partnerships
• Institut de la Vision, Paris, France
Acquisition
• Fovea, Paris, France
ASIA
Biotech
• BioWa, Japan
• Huya, China
• Kitasato Institute research center
for biologicals, Japan
• Kyowa Kirin, Japan
Academia
• Institute of Hematology and Blood
Diseases, Tianjin, China
• Khotro/Khidi, Korea
• SIBS, China
Acquisition
• Shantha Biotechnics, Hyderabad, India
Recent Deal Flow
Overview
REGENERON
ROCKEFELLER
UNIVERSITY
MICROMET
WELLSTAT
THERAPEUTICS
CALIFORNIA INSTITUTE
OF TECHNOLOGY
FOVEA
OXFORDBIOMEDICA
EXELIXIS
BIPAR
ALOPEXX
MERRIMACK
SYNTIRON
KYOWA
HAKKO KIRIN
CUREDM
KALOBIOS
BIOWA
AVIESAN
SHANTHA
BIOTECHNICS
AGAMATRIX
SALK
INSTITUTE
JAN
FEB
Q1 – 09
MAR
APR
MAY
Q2 – 09
JUN
JUL
AUG
Q3 – 09
SEP
OCT
NOV
Q4 – 09
DEC
JAN
FEB
MAR
APR
Q1 – 10
22/23
Industrial Affairs
Sales & Marketing
A global approach to manufacturing
Sanofi-aventis has a broad portfolio of prescription
medicines, vaccines, consumer healthcare (OTC)
products and generics with a market presence
across both traditional and emerging markets.
The group currently has a comprehensive
manufacturing network, with global sites for the
creation of medical equipment, systems and
technologically advanced products; regional sites
dedicated to high volume mass market product
brands; and local factories focused on providing
for national market needs.
In order to manage the growth of its
manufacturing tool, in 2009 the group adopted
a policy of Unique Quality and created an
international and transversal quality organization
structure, uniting the R&D, Manufacturing, sanofi
pasteur and Pharmaceutical Operations teams.
Furthermore, a management team for
Manufacturing Development and Innovation
was created in June 2009. Its purpose is to lead
and manage the lifecycle of the whole portfolio
of products (Innovative Medicines, Consumer
Healthcare, Generics and Medical Equipment) by
developing products and administration systems
that respond to the unmet medical needs of
patients all over the world.
83.3
8
distribution
platforms
3.3
billion
units
produced in 2009
Broad set of Businesses contribute to growth:
SECTORS
2009 NET SALES
SANOFI PASTEUR
3,483
+19.2%
SANOFI PASTEUR MSD
1,132(1)
-11.0%
CONSUMER
HEALTHCARE
1,430
+26.8%
GENERICS
1,012
+198.0%
ANIMAL HEALTH
2,554
+0.4%
(in millions of euros)
CHANGE ON A
COMPARABLE BASIS
(1) Not consolidated
US
EU
Sales2009
(millions euros)
REST OF WORLD
Sales2009
(millions euros)
Sales2009
(millions euros)
€ 9,426 € 12,059 € 7,821
For more information, please visit: ww.sanofi-aventis.com
w
www.sanofipasteur.com
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not
historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified
by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by,
the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates,
the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those
discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to
update or revise any forward-looking information or statements.
Photo credits: sanofi-aventis – Hubert Mouillade and Beatrice Devenes.
“By working together,
let us share our passion
for innovation to make a
difference in patients’ lives”
Updated June 2010 US.COR.10.06.001
Partner to
your idea
Scientific Communications
Sanofi-aventis R&D
1, avenue Pierre Brossolette
91385 Chilly Mazarin cedex, FRANCE
Tel: +33 1 60 49 77 77
www.sanofi-aventis.com